Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714413 · ClinicalTrials.gov registry record · Phase 2
Effect of D-allulose in Addition to Oral Sucrose Load
A Phase 2 study of Blood Glucose, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT02714413: Completed Phase 2 study of Blood Glucose, sponsored by University of Florida.
NCT02714413 is a Phase 2 study of Blood Glucose that has completed, run by University of Florida. The registered enrollment target is 50 participants, roughly in line with the 50-participant average among 4 other Blood Glucose trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02714413, a Phase 2 study of Blood Glucose, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
Individuals in the United States now consume a substantial proportion of their total energy as added sugars. The consumption of caloric sweeteners has been steadily increasing over the last four decades. The potential health consequences of this practice have been subject to considerable debate. In addition to weight gain, higher consumption of sugar-sweetened beverages is associated with development of metabolic syndrome and type 2 diabetes. These findings support the current dietary guidelines that encourage consumers to limit their intake of added sugars. There is a need for a sugar substitute that is safe, palatable and has favorable effects on energy metabolism and overall glucose homeostasis. One such sugar is possibly D-allulose also referred to in the literature as D-psicose. The present proposal is to address the efficacy of D-allulose in reducing postprandial blood glucose level in a random sample of Caucasian and African American population. Specifically the effect of D-allulose ingestion on the glucose and insulin response to a standardized oral glucose load will be studied.
Primary Outcome
Evaluation of the efficacy of pure D-allulose on the glycemic excursion following a standard oral sucrose load.
Conditions Studied
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT D-allulose
- DIETARY_SUPPLEMENT sucrose
Study Locations (1)
Florida
- University of Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-06-30 |
| Phase | Phase 2 |
What the finished NCT02714413 record still lists
NCT02714413 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, roughly in line with the 50-participant average among 4 other Blood Glucose trials with a reported enrollment target.
The record links to 1 condition, with Blood Glucose appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02714413 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT02714413 about?
NCT02714413 is a clinical study titled "Effect of D-allulose in Addition to Oral Sucrose Load". Individuals in the United States now consume a substantial proportion of their total energy as added sugars. The consumption of caloric sweeteners has been steadily increasing over the last four decades. The potential health consequences of this practice have been subject to considerable debate. In ...
What is the current status of trial NCT02714413?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-08. Estimated completion is 2017-06-30.
What conditions does trial NCT02714413 study?
This clinical trial studies the following conditions: Blood Glucose.
What interventions are being tested in trial NCT02714413?
The interventions under investigation include: Placebo (OTHER), D-allulose (DIETARY_SUPPLEMENT), sucrose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02714413?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02714413 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blood Glucose
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Postprandial Response to Fruit Juice
RECRUITING · NA
-
Barley and Rice Mixture Effects on Blood Glucose
COMPLETED · NA
-
Clinical Study of the Intravenous Blood Glucose System in Hospitalized Adult Elective or Non-Emergent Surgery and Medical/Surgical Intensive Care Unit Patients
COMPLETED
-
A Randomized, Crossover Study to Assess the Effects of Dietary Fiber-containing Bars on Glucose and Insulin Responses
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia